Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its earnings results on Monday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12, FiscalAI reports. The company had revenue of $18.62 million for the quarter, compared to analysts’ expectations of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.

Enanta Pharmaceuticals Stock Up 2.4%

Shares of Enanta Pharmaceuticals stock traded up $0.32 on Monday, hitting $13.83. 220,946 shares of the company were exchanged, compared to its average volume of 227,485. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.15. The company has a 50-day moving average price of $14.11 and a 200 day moving average price of $11.29. The stock has a market capitalization of $401.35 million, a price-to-earnings ratio of -3.61 and a beta of 0.98.

Analysts Set New Price Targets

ENTA has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Friday, January 9th. Finally, JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 4,743 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the transaction, the chief executive officer owned 858,026 shares in the company, valued at approximately $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider owned 30,620 shares in the company, valued at approximately $435,722.60. This represents a 6.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 11,961 shares of company stock worth $170,149 over the last three months. Insiders own 11.48% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ENTA. Quarry LP acquired a new stake in Enanta Pharmaceuticals in the third quarter worth about $81,000. Algert Global LLC purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth approximately $133,000. Harvest Investment Services LLC purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $146,000. Public Employees Retirement System of Ohio lifted its stake in shares of Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $186,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.